profiling in two carotid endarterectomy cohorts reveals that CD47 expression is significantly increased in human atherosclerotic plaque, relative to non-diseased vascular tissue (data displayed as Tukey box plots, n = 182 subjects). b, Immunostaining identifies intense CD47 upregulation within the necrotic core of human atherosclerotic coronary artery lesions (left) and carotid plaques (right). c, TaqMan mRNA analysis confirms that vascular CD47 expression progressively increases in a mouse model of atherosclerosis (apoE −/− mice fed high-fat diet, grey), relative to control animals (C57BL/6 mice fed chow, white, n = 4 mice per time point). d, Immunohistochemistry staining with a biotinlabelled antibody (brown) reveals that CD47 expression co-localizes with apoptotic tissue in murine atherosclerotic plaque. * * * P < 0.001, * * P for trend < 0.03. Error bars represent the standard error of the mean (s.e.m.).
such as the tumoricidal macrophage, and is now recognized as a fundamental driver of tumour growth. To determine if dysregulated CD47 may also contribute to atherogenesis, we evaluated its expression in two independent human vascular tissue biobanks 16, 17 . We found that CD47 is consistently upregulated in human atherosclerotic plaque compared to non-atherosclerotic vascular tissue (Fig. 1a) , and in subjects with symptomatic cerebrovascular disease (stroke or transient ischaemic attack) compared to those with stable asymptomatic lesions (Extended Data Fig. 1a ). Because some efferocytosis molecules are known to undergo post-translational modification 18 , we also performed immunofluorescence and immunohistochemical staining of human coronary and carotid arteries, which confirmed that CD47 is progressively upregulated during atherogenesis and appears to localize intensely to the necrotic core ( Fig. 1b , Extended Data Fig. 1b-g) . Similar findings were observed in mouse models of atherosclerosis and other publically available microarray data sets ( Fig. 1c, d , Extended Data Fig. 2 ). Together, these data suggest that pathologic upregulation of 'don't eat me' molecules may explain why phagocytosis is impaired within the human atherosclerotic plaque, which may promote lesion expansion over time.
To determine if this defect could be exploited as a translational target for cardiovascular disease, we treated a cohort of atheroprone animals (apolipoprotein-E-deficient (apoE −/− ) mice implanted with angiotensin-II-infusing minipumps 19 ) with an inhibitory antibody directed against CD47 (Extended Data Fig. 3a ) 15 . Compared to IgG control, anti-CD47 antibody treatment was associated with a marked reduction in atherosclerosis, both in the aortic sinus and en face in the aorta ( Fig. 2a, b , Extended Data Fig. 3b, c) . Similar results were observed in several additional models, including models of chronic atherosclerosis, plaque vulnerability and in mice with established lesions, as would be encountered clinically (Extended Data Fig. 3d-h) . Although anti-CD47 antibodies had no effect on apoptosis in vitro (Fig. 2c, Extended Data Fig. 4a, b) , we observed significantly fewer apoptotic bodies in the lesions of anti-CD47-treated animals in vivo (Fig. 2d ). To reconcile this discrepancy, we used an established in vitro phagocytosis assay, and found that anti-CD47 antibodies potently induced the clearance of diseased and apoptotic vascular SMCs and macrophages that had been exposed to oxidized phospholipids to simulate the atherosclerotic environment ( Fig. 2e , Extended Data Fig. 4c-f) . Similarly, the number of 'free' apoptotic (d) . e, Anti-CD47 antibody promotes efferocytosis of vascular cells at baseline and after exposure to pro-atherosclerotic lipids. Representative FACS phagocytosis plots for lipid-loaded (72 h) SMCs shown on the right (all assays repeated in triplicate). f, In vivo anti-CD47 antibody reduces the number of 'free' apoptotic bodies not associated with phagocytic macrophages, potentially indicative of increased efferocytosis (stars indicate 'free' apoptotic bodies, arrows indicate 'not-free' apoptotic bodies). g, Electron microscopy confirms that mice treated with anti-CD47 antibodies display features of enhanced intraplaque efferocytosis, including an increased prevalence of macrophages which had ingested multiple apoptotic bodies (white arrows) and a reduced burden of 'free' apoptotic bodies (yellow arrows). h, Mice treated with anti-CD47 antibodies develop smaller necrotic cores than mice treated with IgG. i, Anti-CD47 antibody inhibits phosphorylation of lesional SHP1, a key anti-phagocytic effector molecule known to signal downstream of CD47. STS, staurosporine. Comparisons made by twotailed t-tests. * * * P < 0.001, * * P < 0.01, * P < 0.05. Error bars represent s.e.m.
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bodies not associated with an intraplaque macrophage (indicative of failed efferocytosis) was reduced after anti-CD47 antibody treatment in vivo, as suggested by co-localization studies ( Fig. 2f , Extended Data Fig. 5a ) and electron microscopy ( Fig. 2g , Extended Data Fig. 5b ). Ultimately, these animals accumulated less apoptotic debris and developed lesions with smaller necrotic cores ( Fig. 2h , Extended Data Fig. 5c ). From a mechanistic perspective, anti-CD47 antibody therapy was associated with a marked suppression of intraplaque SHP1 phosphorylation, confirming interruption of the anti-phagocytic signalling axis downstream of SIRPα , the cognate anti-phagocytic receptor of CD47 ( Fig. 2i , Extended Data Fig. 5d ). These findings indicate that targeting CD47 can reduce atherosclerosis, and appears to do so by specifically reactivating efferocytosis within the lesion, without altering programmed cell death itself.
In addition to regulating phagocytosis, CD47 is also known to serve as a receptor for the vasoactive and nitric-oxide-regulating cytokine thrombospondin-1 (TSP1) 20 . However, mice treated with anti-CD47 antibodies and IgG control had similar systemic blood pressures (Extended Data Fig. 6a ) and rates of pulmonary nitric oxide elaboration (Griess reaction, Extended Data Fig. 6b ), suggesting that anti-CD47 antibodies did not alter endothelial function in vivo. Further, anti-CD47 antibodies did not influence TSP1 signalling in vitro, having no modifying effect on TSP1-dependent MAPK signalling, eNOS phosphorylation, SMC proliferation or phagocytosis rates (Extended Data Fig. 6c-f ). These data suggest that the anti-CD47 antibodies used in this study mediated anti-atherosclerotic effects independently of TSP1 signalling. Although full-dose anti-CD47 antibody therapy was again found to promote splenic erythrophagocytosis and compensatory reticulocytosis (CD47 is a critical marker of self that is downregulated on ageing red blood cells) 4,15 , this toxicity was self-limited and anaemia was not observed with chronic administration. Otherwise, this proefferocytic agent appeared to be well-tolerated, having no discernible effect on circulating leukocytes, lipid levels, or other metabolic parameters relevant to vascular disease (Extended Data Fig. 6g -u and Extended Data Table 1a ).
To investigate why CD47 is upregulated in atherosclerosis, we used a bioinformatic approach in which we tested for genetic co-expression across panels of mouse and human vascular tissue. This yielded a list of genes that were significantly co-expressed with CD47 in vivo (Extended Data Fig. 7a ). Pathway analyses of these genome-wide data sets identified 'inflammation mediated by chemokine and cytokine signaling pathway' as the top pathway associated with CD47 in vascular tissue (Extended Data Fig. 7b and Extended Data Table 1b, c), and specifically implicated TNF-α as the factor most likely to function as its upstream regulator ( Fig. 3a ). Subsequent correlation studies identified a strong positive association between CD47 and both the canonical TNF receptor, TNFR1 (Fig. 3b ), as well as TNF-α itself ( Fig. 3c ), in human atherosclerotic vessel specimens. Similarly, CD47 expression levels were correlated with TNF-α levels in tissue from atherosclerotic mice and confirmatory human data sets (Extended Data Fig. 7c, d ). Together, these informatics and co-expression studies implicate TNF-α -a proinflammatory cytokine known to be upregulated in atherosclerosis-in CD47-dependent vascular disease 21,22 .
To investigate the causality of these associations, we next tested whether CD47 is directly downstream of TNF-α . We found that treatment of vascular SMCs with recombinant TNF-α led to a 
consistent upregulation of cellular CD47 expression, whereas no effect was observed with a variety of other common pro-atherosclerotic or proinflammatory insults (Extended Data Fig. 7e -h). Further, TNF-α blunted the progressive decrease in CD47 expression normally expected to occur during programmed cell death ( Fig. 3d -f, Extended Data Fig. 7i -l). As a result of their higher levels of anti-phagocytic molecules, TNF-α -treated cells were less likely to be phagocytosed by macrophages, particularly when concomitantly exposed to oxidized low-density lipoproteins (oxLDL) and pro-apoptotic stimuli ( Fig. 3g , Extended Data Fig. 7m ). Because impaired efferocytosis is known to incite proinflammatory cytokine elaboration 9 , it is possible that a positive feedback loop underlies the co-localization of TNF-α , CD47, and uncleared pathological cells and apoptotic bodies within the atherosclerotic plaque 22 . Analysis of the CD47 promoter in vascular SMCs revealed a region of open chromatin predicted to contain binding sites for several of the NF-κ B transcription factors known to be downstream of TNFR1 (Extended Data Fig. 8a and Extended Data Table 1d ). Among these, the classical proinflammatory factor NF-κ B1 (p50) was found to be positively correlated with CD47 expression in both human coronary and carotid plaques ( Fig. 4a , b, Extended Data Fig. 8b ). Luciferase reporter assays performed with a vector containing the CD47 promoter revealed that TNF-α treatment stimulated basal CD47 expression, and that the effect was specifically enhanced when NF-κ B1was simultaneously overexpressed in these cells ( Fig. 4c , Extended Data Fig. 8c-e ). Chromatin immunoprecipitation assays confirmed that NF-κ B1 binds to the CD47 promoter in vitro, and that this occupancy is increased several fold upon treatment with TNF-α ( Fig. 4d , Extended Data Fig. 8f ).
From a translational perspective, we found that anti-CD47 antibodies were able to stimulate efferocytosis in TNF-α -treated cells, and that the effect was most pronounced under dyslipidaemic, pro-atherosclerotic conditions ( Fig. 4e ). A modest incremental benefit was observed when anti-CD47 antibody therapy was combined with commercially available anti-TNF-α therapies, such as infliximab or etanercept, probably because of their inhibitory influence on CD47 expression in mouse and human tissue ( Fig. 4f , g, Extended Data Fig. 9 ). These data are particularly provocative given the observation that patients prescribed TNF-α -inhibiting antibodies for inflammatory disorders such as lupus and rheumatoid arthritis appear to be protected from myocardial infarction 21, 23 .
The finding that CD47 expression is pathologically upregulated in both cancer and cardiovascular disease suggests a commonality between these two conditions. In leukaemogenesis, cancer stem cells out-compete normal haematopoietic stem cells, while countering signalling associated with programmed cell removal; viable myelodysplastic syndrome haematopoietic oligolineage progenitors express the phagocytic signal calreticulin, but not CD47, whereas acute myeloid leukaemia derived from myelodysplastic syndromes are positive for CD47 expression 24 . Similar cellular processes in the vasculature may explain the recent observations that de-differentiated SMCs undergo clonal expansion within the atherosclerotic plaque 25,26 . Furthermore, the top cardiovascular locus identified by genome-wide association studies surprisingly resides near an important tumour suppressor locus 27 , which in turn regulates SMC efferocytosis 17 . Future studies will need to examine whether expansion of CD47 hi SMC clones contributes to atherosclerosis, and if their clearance can be accomplished without the induction of anaemia (for example, with a dose-escalation approach that appears to be safe in non-human primates 28 and is currently being pursued in first-in-human clinical trials 29 ).
Together, these data provide insights into why programmed cell removal is impaired in the atherosclerotic plaque, and how this may Pearson correlation coefficients were determined assuming a Gaussian distribution and P values were determined using a two-tailed test. c, Dual luciferase reporter assays reveal that CD47 promoter activity is stimulated in cells treated with TNF-α (top), but that this effect is significantly enhanced in cells co-transfected with an NF-κ B1 expression vector. d, Chromatin immunoprecipitation studies confirm significant enrichment of NF-κ B1 protein on the CD47 promoter in TNF-α -treated human coronary artery SMCs. e, In vitro efferocytosis assays reveal that anti-CD47 antibody enhances the clearance of cells exposed to TNF-α , and that its proefferocytic capacity is enhanced under pro-atherosclerotic conditions. f, Pretreatment with the anti-TNF-α monoclonal antibody infliximab prevents the upregulation in Cd47 mRNA that normally occurs in SMCs exposed to TNF-α . g, Concomitant inhibition of CD47 and TNF-α using anti-CD47 antibodies and infliximab, respectively, produces synergistic benefit in the clearance of diseased vascular cells, as assessed by ANOVA. h, Putative mechanism explaining why efferocytosis is impaired in cardiovascular disease, and how inhibition of CD47-SIRPα signalling could represent a new therapeutic target. Comparisons made by two-tailed t-tests, unless otherwise specified. * * * P < 0.001, * * P < 0.01, * P < 0.05. Error bars represent s.e.m.
promote lesion expansion. Our findings bolster the 'inflammatory hypothesis' of atherosclerosis 30 , and specifically link cytokine signalling with anti-phagocytic signalling in vascular disease. Given the experimental success of pro-efferocytic therapies in the oncology field using antibodies that block the CD47 signal 5 , it is possible that these findings will provide a novel nonsurgical treatment of cardiovascular disease (mechanism shown in Fig. 4h ).
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.

METHODS
Data reporting. The experiments were not randomized. The investigators were not blinded to allocation during experiments, but were blinded during data analysis and interpretation. No statistical methods were used to predetermine sample size. Human cardiovascular tissue. Carotid endarterectomy samples. In this study, a total of 182 human carotid endarterectomy samples and nonatherosclerotic control arteries were used. These include heterogeneous atherosclerotic plaque samples obtained from patients undergoing surgery for symptomatic (stroke or transient ischaemic attack) or asymptomatic (no history of cerebrovascular event) high-grade carotid stenosis (> 50% NASCET criteria) as part of the Biobank of Karolinska Endarterectomies (BiKE). 15 nonatherosclerotic control arteries (iliac artery and aorta) were obtained from organ donors without any history of cardiovascular disease. Patients were consecutively enrolled in the study, with the first 127 constituting the discovery cohort (40 asymptomatic, 87 symptomatic) and the next 50 constituting the validation cohort (10 asymptomatic, 40 symptomatic). All samples were collected with informed consent from patients, organ donors or their guardians. The BiKE study was approved by the Ethical Committee of the Northern Stockholm. DNA and RNA was extracted from these specimens and analysed by Ilumina 610w -QuadBead SNP-chips and the Affymetrix HG-U133 plus 2.0 microarrays (discovery cohort) or the Affymetrix HG-U133a Genechip arrays (validation cohort), as previously described 16, 17 and deposited in Gene Expression Omnibus (accession number GSE21545). Robust multi-array average (RMA) normalization was performed and processed gene expression data was returned in log 2 -scale. The relative expression of each gene was determined by comparing the pixel intensity of the 11 probe pairs which correspond to each transcript to the 'normalization control set' specific to each array (see http://www.affymetrix.com/ support/technical/technotes/expression_comparison_technote.pdf and http:// www.affymetrix.com/support/technical/datasheets/hgu133arrays_datasheet.pdf). Student's t-test with correction for multiple comparisons according to the Sidak-Bonferroni method was used for statistical analyses of microarray data. Pearson's correlations were calculated to determine associations between expression of the gene of interest and other genes from microarrays. Publically available data from the Helsinki Carotid Endarterectomy Study (HeCES) were analysed as a second human validation cohort 31 . Additional publically available vascular and nonvascular microarray data deposited in GEO were also analysed (as indicated by GSE number in the corresponding figure legend), including studies of microdissected atherosclerotic plaques and samples taken from individuals treated with commercially available TNF-α inhibitors. A P value < 0.05 was considered to indicate significance. Coronary artery samples. In this study, a total of 114 human coronary artery samples were used. 51 atherosclerotic epicardial coronary artery segments were harvested from 22 orthotopic heart transplant donors, as previously described 32 . Additionally, 56 coronary artery segments were extracted from atherosclerotic intracoronary plaques in patients undergoing coronary atherectomy, as previously described 33 . Briefly, longitudinal atherectomy was performed with the Silverhawk atherectomy catheter in arteries with flow-limiting stenosis after diagnostic angiography. RNA was isolated from both sets of specimens and hybridized to custom dual-dye gene expression microarrays representing approximately 22,000 features 32, 33 . Briefly, the custom probe set was identified from data mining and curation of atherosclerosis and vascular cell-culture-based expression analyses and combined with the Agilent Human 1A and 1B arrays. In each microarray experiment, the expression levels of CD47 were determined by array-specific hybridization probe sets (~ 10 per transcript). Automated feature extraction software was used to filter out background or saturated spot intensities to eliminate inherent probe and spatial biases during the fluorescent detection. This software computes the log 2 ratios and filters features by P value. These values were normalized according to protocol for each array, using a locally weighted linear regression curve fit (LOWESS) to correct for dye biases. This normalization procedure results in array specific log 2 ratios, and provides accurate measures of relative gene expression differences (http://www. affymetrix.com/support/technical/datasheets/human_datasheet.pdf). Normalized data from candidate transcripts were then used to calculate a Pearson correlation coefficient r assuming a Gaussian distribution, and two-tailed P values were calculated for each correlation coefficient.
In addition to samples obtained for RNA analysis, an additional seven right coronary arteries were obtained from rapid autopsies from adult patients with a spectrum of coronary artery disease for histological analysis. The arteries were fixed with 4% paraformaldehyde (PFA) for several hours, and immersed in 30% sucrose at 4 o C overnight. The coronaries were then serially sectioned and segments of atheroma and relatively normal coronary artery were embedded in paraffin or OCT, and sectioned at 7-μ M thickness.
For immunohistochemical staining, paraffin slides were deparaffinized and rehydrated with xylene and alcohol gradients, and antigen retrieval was performed in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) using a pressure cooker. The sections were blocked with 5% goat serum, and then stained with primary antibodies (anti-CD47, Abcam B6H12.2, 2 μ g ml −1 ) or mouse IgG1 kappa (eBioscience, 2 μ g ml −1 ) at 4 °C overnight. The sections were washed in TBS, incubated with MACH4 kit (Biocare Medical) according to the manufacturer's instructions, and then detected using the Vulcan Fast Red Chromogen kit2 (Biocare Medical). Staining for SMC content was accomplished by washing sections in water and PBS, followed by incubation with anti-SM22 alpha antibodies (Abcam, ab14106, 1:300). The sections were washed with PBS, incubated with Alexa Fluor 488 goat anti-Rabbit (Life technologies, 1:250), washed, and mounted with Vectashield Mounting medium with DAPI (Vector Laboratories). Pictures were taken by Nikon digital camera mounted on an inverted fluorescence microscope. Serial sections were prepared as described above, and also stained with Masson's trichrome (Richard-Allan), or haematoxylin and eosin (Richard-Allan). For the staining of frozen sections, OCT was removed in water, and the sections were stained with Oil Red O (ORO, Sigma-Aldrich, O0625, 0.5%), haematoxylin and eosin (H&E, Richard-Allan), smooth muscle alpha-actin (Abcam, ab5694, 1:300), HMGB1 (Abcam, ab18256, 1:100), CD206 (Abcam, ab64693, 1:50), CD47 (Abcam B6H12.2 or Novus Biologicals, #NBP2-31106, 1:50) or mouse IgG1 kappa (eBioscience). Secondary antibodies included Alexa Fluor 594 goat anti-mouse (Life technologies, A11005, 1:300) and Alexa Fluor 488 goat anti-rabbit (Life technologies, A11034, 1:300). Antibody specificity was confirmed using isotype control and by preincubating the anti-CD47 antibodies with recombinant CD47 antigen (R&D Systems) in a 1:5 ratio for 16h at 4 °C before application. High resolution imaging of the carotid sections was performed as previously described 34 . Murine cardiovascular tissue. Atherosclerosis models. In the atherosclerosis studies described below, a total of 179 male apoE-deficient mice on the C57BL/6 background (apoE −/− , Jackson Laboratory, catalogue #002052) were used.
In the main atherosclerosis intervention studies, 8-week-old mice were implanted with subcutaneous Alzet minipumps (model 2004, Alzet Osmotic Pumps) containing Angiotensin II (AngII, Sigma-Aldrich, 1000 ng kg −1 min −1 ) and initiated on a high fat Western diet (21% anhydrous milk fat, 19% casein and 0.15% cholesterol, Dyets no. 101511) for the ensuing 4 weeks, as previously described 19 . To determine the effect of CD47 signalling on vascular disease, mice were injected with either 200 μ g of the inhibitory anti-CD47 antibodies (MIAP410, BioXcell, n = 18) or IgG1 control (MOPC-21, BioXcell, n = 20) IP QOD, at the dose previously studied 15 . The antibody therapy was started one day before the pump implantation. Animals were observed daily, and in the case of premature sudden death, necropsy was performed to determine the cause of mortality. Blood pressure in conscious mice was measured at baseline (after standard acclimatization with a Visitech Systems Inc. machine), and weekly for the duration of the study. At 12 weeks of age, the mice were killed after an overnight fast, with serum and visceral organs (including the aortae) isolated and processed for analysis.
In the chronic atherosclerosis studies, male apoE-deficient mice were weaned and initiated on a high fat diet at 4 weeks of age and maintained on this for the subsequent 12 weeks (without any angiotensin infusion). Antibody injection was performed as described above while the high fat diet was given (n = 9 per condition), and the animals were killed at the age of 16 weeks.
In the established disease model, apoE-deficient mice were weaned onto a high fat diet at 4 weeks of age and continued on this for the ensuing 8 weeks (without any angiotensin infusion). At 12 weeks of age (after lesions had developed), mice were initiated on 200 μ g of anti-CD47 antibodies (n = 14) or IgG1 (n = 13) IP QOD for the ensuing 6 weeks, and killed at 18 weeks of age.
In the TNF-α inhibitor synergy studies 8-week-old apoE-deficient mice were implanted with AngII pumps and maintained on Western high-fat diet, and then randomized to one of four groups, including the: ). In this model, the antibody treatment was started the day before AngII pump implantation and delivered for 4 weeks, and the mice were euthanized at 12 weeks of age. Note that in this model, the anti-CD47 antibody dose was reduced by 75% to determine whether a lower dose of therapy could also affect atherogenesis.
In the short-term intervention model, 8-week-old apoE-deficient mice were implanted with AngII pumps and maintained on Western high-fat diet without antibody therapy for the ensuing 23 days. Beginning at day 23, the mice received SQ injections of either: (1) IgG daily, n = 10; (2) etanercept (0.8 mg per kg at day 23, n = 6); (3) anti-CD47 antibody (200 μ g of MIAP410 daily, n = 11); or (4) combination therapy, n = 11 between days 23 and 27. This cohort of mice was killed after only 5 days of antibody treatment (at day 28) and was used to evaluate the effect of antibody therapy in established atherosclerotic plaques of identical size.
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To evaluate the effect of antibody therapy on atherosclerotic plaque vulnerability, we used the recently described 'tandem stenosis' model 35 . At 6 weeks of age, apoE-deficient mice were initiated on high-fat diet and maintained on this for ensuing 6 weeks. At 12 weeks of age, tandem stenoses were introduced in a manner shown to reproducibly alter shear stress and induce plaque rupture, as previously described 35 . Briefly, the mice were anaesthetized by isoflurane inhalation and an incision was made to allow dissection of the right common carotid artery from the circumferential connective tissues. Serial stenosis with a 150 μ m outer diameter were then introduced 1 mm and 4 mm from the carotid bifurcation. The stenosis diameter was obtained by placing a 6-0 suture around the carotid artery together with a 150 μ m needle that was tied to it and later removed. Antibody therapy was started the day before the surgery and continued thereafter. Mice were killed 7 weeks after the surgery and intraplaque haemorrhage was quantified within the processed tissue sections.
In addition to the mice treated with anti-CD47 antibody or control antibody, a separate cohort of 12 male apoE −/− mice were fed a high-fat diet for either 8, 12 or 20 weeks, but were not treated with antibody nor implanted with osmotic minipumps. These mice were used to determine aortic gene expression changes during atherogenesis, using the RNA analysis methods described below. In these experiments, comparison was made to control C57BL/6 mice fed standard chow diet for 24 weeks.
Finally, a cohort of 3 apoE −/− mice were implanted AngII osmotic pump and fed a high-fat diet for 4 weeks (but not treated with antibody) and then injected with biotin-labelled anti-CD47 antibodies 24 and 6 h before being killed, to determine where the therapeutic antibody accumulates in vivo. Nonatherosclerotic C57BL/6 and CD47-deficient mice (Cd47 −/− , Jackson Laboratory, catalogue #003173) were also injected with the biotin-labelled antibodies, and served as controls. All animals were analysed as described below. Vascular tissue preparation, immunohistochemistry and atherosclerotic lesion quantification. Aortic atherosclerosis lesion area was determined as described previously 17 . Briefly, the arterial tree was perfused with PBS and then fixed with 4% PFA. The heart and the full-length of the aorta-to-iliac bifurcation was exposed and dissected carefully from any surrounding tissues. Thoracic aortas were then opened along the ventral midline and dissected free of the animal and pinned out flat, intimal side up, onto black wax. Aortic images were captured with a digital camera mounted on a Nikon stereomicroscope and analysed using Adobe Photoshop CS5 software. The percentage of lesion area was calculated as total lesion area divided by total surface area. The atherosclerotic lesions within the aortic valve area (aortic sinus) were analysed as described previously 17 . The samples were perfused with PBS, fixed with 4% PFA, embedded in OCT, and sectioned at 7-μ M thickness. Four sections at 100-μ M intervals were collected from each mouse and stained with ORO, Masson's trichrome, haematoxylin and eosin, smooth muscle α -actin (SMA, Abcam, ab5694, 1:300), Mac-3 (BD Sciences, BD 550292, 1:100), CD-3 (Abcam, ab5690, 1:150), and Ly-6G (BD Sciences, BD 551459, 1:300). Atherosclerosis burden was quantified from the luminal aspect of the blood vessel through the plaque to the internal elastic lamina (that is, lipid in the neointima was quantified). Necrotic core size was quantified by calculating the area of the lesion which was acellular on Masson's trichrome staining, as previously described 17, 36 . Plaque haemorrhage was quantified by determining the presence or absence of red blood cells (TER-119, Santa Cruz Biotechnology) within the plaque, as previously described 37 . Subsequent immunohistochemical studies were quantified from the luminal aspect of the blood vessel through the plaque to the external elastic lamina (to assess changes which also involved the tunica media). To detect the localization of injected biotin-labelled anti-CD47 antibodies, the avidin-biotin complex technique was used. Frozen sections of aortic sinus were prepared from the mice injected with biotin-labelled anti-CD47 antibodies, as described above. Endogenous peroxide activity was blocked by incubation with 0.3% hydrogen peroxide for 30 min, and the sections were washed with water and PBS, followed by blocking with 5% goat serum for 30 min. Biotin was detected using Vecstatin ABC kit and DAB substrate kit per protocol (Vector laboratories). Corresponding aortic sinus sections from the mouse without biotin antibody injection were used as negative controls, as were Cd47 −/− mice which had been injected as above. For immunoflourescent staining of these samples, sections were blocked with 5% goat serum for 30 min, then incubated with Streptavidin-Alexa Fluor 546 conjugate (Life Technologies, 1:300) and Mac-3 (BD, 1:100) for 1 h, followed by Alexa Fluor 488 donkey anti-rat (Life Technologies, 1:300). In vivo apoptosis was assessed by staining for TUNEL positivity with the Cell Death Detection Kit (Roche), per protocol, and confirmed with cleaved caspase 3 (Cell Signaling #9661, 1:200) staining followed by Alexa Fluor 488 goat anti-rabbit (Life technologies, 1:250). The cleaved-caspase-3-positive area was measured and quantified using Adobe Photoshop, and the percentage of positive area was calculated as total caspase-3-positive area divided by total atherosclerotic plaque area measured by ORO staining in the serial sections. To calculate the in vivo phagocytic index, we performed double staining of cleaved caspase 3 (detected with Alexa Fluor 488 goat anti-rabbit antibody) and Mac-3 (detected with Alexa Fluor 594 goat antirat antibody (Life technologies, 1:250)). The number of free apoptotic cells not associated with a macrophage (indicated by a star (Fig. 2f) ) was manually assessed in a blinded fashion, and compared to apoptotic cells associated with a macrophage (indicated by an arrow), as previously described 2 . For phospho-SHP1 staining, the sections were stained with phospho-SHP1 antibodies (Abcam, ab131500, 1:50) and Mac-3 followed by Alexa Fluor. The phospho-SHP1-positive area was normalized to Mac-3-positive area. All lesion areas and indices were measured and quantified using Adobe Photoshop by a blinded observer. Samples collected from several tissue beds were also snap-frozen in liquid nitrogen for subsequent mRNA and protein expression analysis, as described below. Vascular tissue electron microscopy. Electron microscopy was performed in the Stanford University Cell Sciences Imaging Facility, as previously described 17 . Briefly, samples were fixed and processed using standard histologic techniques then imaged using a JEOL JEM-1400 transmission electron microscope. Ingested apoptotic bodies (indicated by white arrow (Fig. 2g) ), free apoptotic bodies (indicated by yellow arrow), and apoptotic bodies undergoing secondary necrosis (indicated by red arrow) were qualitatively assessed in a blinded manner, as previously described 17 . Serum and plasma analysis. Serum chemistry, lipid, complete blood count, and differential analyses were performed by the Stanford Animal Diagnostic Laboratory, as previously described 17 . In brief, blood samples were collected by cardiac puncture after an overnight fast. Automated haematology was performed on the Sysmex XT-2000iV analyser system. Blood smears were prepared for all full complete blood count samples and reviewed by a medical technologist. Chemistry analysis was performed on the Siemens Dimension Xpand analyser, and included analyses of renal function, electrolyte levels, liver function tests, fasting glucose levels and fasting lipid panels. A medical technologist performed all testing, including dilutions and repeat tests as indicated, and reviewed all data. Serum insulin levels were measured by ELISA kit according to the manufacturer's instruction (EMD Millipore). Griess reaction. The activity of nitric oxide synthase was evaluated using a modified Griess assay. Lung samples were collected from mice and snap-frozen by liquid nitrogen before homogenization in PBS. The nitrate and nitrite levels were measured by Ultrasensitive Colorimetric Assay for nitric oxide synthase (Oxford Biomedical Research) according to the manufacture's instructions, and standardized by the protein amount. Hybrid Mouse Diversity Panel. The Hybrid Mouse Diversity Panel (HMDP), which includes a quantitative analysis of 109 classical and recombinant inbred mouse strains 38 , was used to identify factors associated with vascular CD47 expression, in vivo. Briefly, whole aorta from the arch to the mid-abdomen was snap-frozen at the time of death and total RNA was isolated using the RNeasy kit (Qiagen), as described 39 . Genome-wide expression profiles were determined by hybridization to Affymetrix HT-MG_430 p.m. microarrays on a subset of female mice from 104 strains (n = 2 aorta per strain). Quantification of plasma cytokines was carried out in a multiplexed immune-capture microbead system (Milliplex Mouse Cytokine/Chemokine Magnetic Bead Panel MCYTOMAG-70K, EMD Millipore) as per the manufacturer's instructions. Cytokines profiled were: G-CSF, GM-CSF, IFNr, IL-1α , IL-1β , IL-2, IL-4, IL-6, IL-7, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IP-10, KC, MCP-1, MIP-1α , MIP-1β , M-CSF, MIP-2, MIG, RANTES, TNF-α . Plasma insulin was measured using the mouse insulin ELISA kit (80-INSMS-E01, Alpco) as per the manufacturer's instructions. Pearson's correlations were generated to calculate transcript-transcript and transcript-trait correlations. Using these methods, the genes and plasma cytokines that were significantly associated with aortic CD47 expression levels were identified. In silico bioinformatics methods. Pathway analysis. Genome-wide correlation analyses were performed to identify genes that are significantly correlated with CD47 expression in the human and murine vascular tissue collections described above. These lists were intersected to identify genes that are commonly coexpressed across multiple data sets in both species. The resulting list of genes (Extended Data Fig. 7a ) was subjected to a series of bioinformatics analyses including the Database for Annotation, Visualization and Integrated Discovery (DAVID), Kyoto Encyclopedia of Genomes and Genes (KEGG), Gene Ontology (GO), and Protein Analysis Through Evolutionary Relationships (PANTHER) classification. Additionally, genes were mapped to open chromatin regulatory intervals in primary human vascular cells and analysed using the Genomic Regions Enrichment of Annotations Tool (GREAT). Pathways found to be overexpressed were ranked by P value. Statistical overrepresentation and enrichment analyses were performed using Bonferroni correction for multiple testing (P < 0.05 cutoff).
Ingenuity Pathway Analysis (IPA) was then performed on the resulting intersected CD47 co-expression gene list from human carotid atherosclerosis (BiKE study) and murine aortic atherosclerosis (HMDP study). Briefly, the 63 gene identifiers and expression values were analysed using the Core pathway analysis after removing any duplicates and unmapped identifiers. The resulting networks were then subjected to an Upstream Regulators Analysis using the Ingenuity Knowledge Base after applying a filter to include all genes, RNAs and proteins, while excluding chemicals or drugs. Overlap P values were calculated for each upstream regulator using a Fisher's exact test and activation z-scores were calculated by comparing observed direction of target genes with inferred literaturederived regulatory direction to identify the most significant upstream regulators for CD47. Promoter analysis. Using the UCSC browser, the genetic sequence 1 Kb upstream of the CD47 promoter was identified and analysed, as previously described 17 . In addition to evaluating for open chromatin status and DNase hypersensitivity sites, potential transcription factor binding sites (TFBS) were predicted using the following online bioinformatics tools: TRANSFAC (BIOBASE), P-Match, TFSearch, Alibaba, PROMO, and MatInspector. High confidence binding sites (85% likelihood cutoff) were accepted for additional analysis. Additionally, the predicted binding sites in the CD47 promoter region were intersected with open chromatin peaks identified from the assay for transpose accessible chromatin followed by sequencing (ATAC-seq) in primary human coronary artery SMCs (HCASMC). Cell culture. Primary vascular SMCs were collected from the aortas of C57BL/6 mice and propagated in DMEM supplemented with 10% FBS, as previously described 17, 40 . Human coronary artery SMCs (HCASMC, Lonza Catalog CC-2583, passage 3-6) were propagated in SmGM-2 growth media (Lonza) containing 5% FBS. To obtain human macrophages, leukocyte reduction system (LRS) chambers were obtained from the Stanford Blood Center from anonymous donors. Monocytes were purified on an autoMACS Pro Separator (Miltenyi) using wholeblood anti-CD14 microbeads (Miltenyi) and differentiated to macrophages by culture for 7-10 days in IMDM+ GlutaMax (Invitrogen) supplemented with 10% AB-human serum (Gemini Bio-Products 100-512) and 100 U ml −1 penicillin and 100 μ g ml −1 streptomycin (Invitrogen). RFP + mouse macrophages were generated and evaluated as previously described 41 . Briefly, bone-marrow cells were isolated from C57BL/Ka Rosa26 mRFP1 transgenic mice and differentiated in IMDM + GlutaMax supplemented with 10% fetal bovine serum, 100 U ml −1 penicillin and 100 μ g ml −1 streptomycin, and 10 ng ml −1 murine M-CSF (Peprotech). Mouse yolk sac endothelial cell line (C166, ATCC, CRL-2581) and mouse macrophage cell line (RAW 264.7, ATCC, TIB71) were grown in DMEMgrowth media containing 10% FBS, while mouse T-lymphocyte cell line (EL4, ATCC, TIB-39) were grown in DMEM containing 10% horse serum. Human macrophage cell line (THP1, ATCC, TIB-202) were grown in RPMI-1640 medium containing 10% FBS and 0.05 mM 2-mercaptoethanol. Human embryonic kidney cells (HEK-293, ATCC, CRL-1573) used for luciferase reporter assays were grown in DMEM-growth media containing 10% FBS. No additional cell authentication or mycoplasma contamination testing was performed.
A variety of atherosclerosis-related or pro-apoptotic stimuli were applied to the cells in the experiments described below including: oxidized LDL (oxLDL, 50 μ g ml −1 , Alfa Aesar), Ang II (100 nM, Sigma-Aldrich), fibroblast growth factor (FGF, 100 ng ml −1 , R&D), platelet-derived growth factor (PDGF, 100 ng ml −1 , R&D), and lipopolysaccharide (LPS, 1 μ g ml −1 , Sigma-Aldrich). Additionally, a number of cytokines associated with CD47 expression through the HMDP Luminex array were also tested, including tumour necrosis factor α (TNF-α , 50 ng ml −1 , R&D), interleukin 2 (IL-2, 100 ng ml −1 , Biolegend), chemokine receptor ligand 1 (CXCL1, 100 ng ml −1 , Biolegend), interleukin 4 (IL-4, 50 ng ml −1 , Biolegend), and transforming growth factor β (TGF-β , 50 ng ml −1 , R&D). Before experimentation, SMCs were serum-starved for 24 h in DMEM and then stimulated with the stimuli listed above for 24 h before analysis. In some experiments, the cells were stimulated with staurosporine (STS, 1 μ M, Sigma-Aldrich) for 1 or 4 h to induce apoptosis, after 24 h of TNF-α treatment.
To inhibit TNF-α signalling, a chemical inhibitor (SPD 304, Sigma Aldrich) or a monoclonal antibodies (Infliximab, Janssen) were used. Briefly, TNF-α was pre-incubated with 10 μ M of SPD304 or 100 μ g ml −1 of infliximab in serum free DMEM for 20 min before cell stimulation. To inhibit NF-κ B signalling, the cells were pre-treated with 10 μ M BAY 11-7085 (Santa Cruz Biotechnologies) or DMSO, then stimulated with TNF-α .
For MAPK western blotting experiments, mouse aortic SMCs were serumstarved for 48 h, pre-treated with 10 μ g ml −1 of CD47 antibodies or IgG for 20 min, then stimulated with thrombospondin-1 (TSP1, 10 μ g ml −1 , R&D) for 10 or 30 min. For eNOS western blotting experiments, C166 cells were serum-starved for 8 h, pre-treated with 2 μ M TSP1 with or without 10 μ g ml −1 of CD47 antibody or IgG for 20 min, then stimulated with acetylcholine (Ach, 10 μ M, Sigma-Aldrich) for 15 min. mRNA isolation and quantitative reverse-transcription PCR. RNA was isolated from cell lysates using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. RNA was isolated from murine organ samples using the Trizol method (Invitrogen). RNA was quantified with the Nanodrop machine (Agilent Technologies). For quantitation of gene transcription, cDNA was generated with MultiScribe reverse transcriptase (Applied Biosystems), and then amplified on the ABI PRISM 7900HT with commercially available TaqMan primers (Applied Biosystems) and normalized to 18S internal controls, as previously described 17 . A list of the primers and probes used in these studies is provided in Extended Data Table 1e . Protein extraction and western blotting. Total protein was isolated from cultured cell lines and tissue homogenates using 1× cell lysis buffer (Cell Signaling) supplemented with 1× Halt Protease & Phosphatase Single-Use Inhibitor Cocktail (Thermo Scientific), as previously described 17 . The protein concentration in each sample was measured using Pierce BCA Protein Assay Kit (Thermo Scientific). Equal amounts of protein were loaded and separated on precast gels (Bio-Rad) and thereafter transferred onto PVDF membranes (Bio-Rad). Following a 1 h incubation in 5% bovine albumin serum solution prepared in 1× TBST, these membranes were probed with commercially available antibodies designed to recognize endogenous P38 (Cell Signaling, 1:1000), phospho-P38 (Cell Signaling, 1:1000), ERK1/2 (Cell Signaling, 1:1000), phospho-ERK1/2 (Cell Signaling, 1:1000), phospho-eNOS (Cell Signaling, 1:1000), CD47 (Novus Biologicals, 1:1000) and GAPD (1:1000; Cell Signaling Technologies) overnight at 4 °C. Membranes were rinsed with TBST and incubated with appropriately matched horse-radish peroxidase (HRP)-conjugated anti-mouse (1:5000; Life Technologies) or anti-rabbit (1:5000; Life Technologies) antibodies for 1 h, before protein expression was detected using SuperSignal West Pico Chemiluminescent substrate (Thermo Scientific). Membranes were then scanned with a Licor Odyssey Fc imager for quantitative analysis. In some experiments, membranes loaded with protein were incubated with anti-CD47 antibody that had been preabsorbed with CD47 peptide (R&D systems, 1866-CD, 1:5 dilution) for 16 h, to determine the specificity of the primary antibody. Apoptosis assays. To evaluate apoptosis, the luminometric Caspase-Glo 3/7 Assay (Promega, G8090) was performed on cultured cells, according to the manufacturer's protocol. Briefly, mouse aortic SMCs were seeded in 96-well plates at the density of 10,000 cells per well, grown at 37 °C for 24 h, and then serumstarved for 24 h. Apoptosis was induced with 1 μ M STS treatment for 4 h in the presence of 10 μ g ml −1 of anti-CD47 antibodies or IgG. Confirmatory assays were performed by flow cytometry, where cells where exposed to 24 or 72 h of vehicle, 50 ng ml −1 of TNF-α , or 50 μ g ml −1 of oxLDL, then treated with 1 μ M STS for 4 h before being collected in TrypLE. These cells were stained with anti-annexin V antibody labelled with fluorescein isothiocyanate (FITC) and propidium iodide (eBioscience) and analysed by Scanford cell analyser (Stanford Shared facility, Stanford), as previously described 42 . These FACS data was analysed by FlowJo 10.1r5. Proliferation assays. A modified MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5diphenyltetrazolium bromide) assay was performed to analyse SMC proliferation and viability. Mouse aortic SMCs were seeded in 96-well plates at the density of 6,000 cells per well, grown at 37 °C overnight, and then serum-starved for 48 h. The cells were stimulated with 10% serum or 10 μ g ml −1 TSP1 with or without 10 μ g ml −1 of anti-CD47 antibodies or IgG for 24 h and then incubated for 4 h in the presence of 10 μ l of MTT AB solution (Millipore). The formazan product was dissolved by addition of 100 μ l acidic isopropanol (0.04 N HCl) and absorbance was measured at 570 nm (reference wavelength 630 nm) on an ELISA plate reader by SpectraMax 190 Microplate Reader (Molecular Devices). Efferocytosis assay. Standard in vitro phagocytosis assays were performed as previously described 41 . SMCs were labelled with 2.5 μ M carboxyfluorescein succinimidyl ester (CFSE) according to the manufacturer's protocol (Invitrogen). 100,000 SMCs were plated per well in a 96-well plate (Corning) and pre-incubated with antibody (IgG1 isotype control (MOPC-21) or MIAP410 (anti-CD47)) for 30 min at 37 °C. An unrelated anti-CD8 antibody was also tested as a negative control. After 30 min, 50,000 macrophages were added to each well and co-incubated for 2 h in serum-free medium, then analysed using an LSRFortessa cell analyser with high throughput sampler (BD Biosciences). RFP + mouse macrophages were identified by intrinsic fluorescence. Dead cells were excluded from the analysis by staining with DAPI (Sigma). Phagocytosis was evaluated as the percentage of GFP + macrophages using FlowJo X 10.0.7r2 (Tree Star) and was normalized to the maximal response by each independent donor against each cell line. In addition to measuring basal efferocytosis rates, experiments were repeated with target cells that had been pretreated with a variety of compounds (alone or in combination) including STS, oxLDL, TNF-α , TSP1, and infliximab. Confirmatory assays were LETTER RESEARCH performed with RAW macrophages where target cells were labelled with 1 μ M of CellTracker Deep Red dye (Life technologies) and phagocytes were labelled with 1.25 μ M of CellTracker Orange CMRA (Life technologies) at 37 °C for 30 min. As above, cells in these assays were treated with 50 μ g ml −1 of oxLDL, 50 ng ml −1 of TNF-α , or 100 μ g ml −1 of infliximab antibody for 24 h before co-culture in serumfree medium with 10 μ g ml −1 of antibody of IgG1 isotype control (MOPC-21) or anti-CD47 (MIAP410) for 2 h at 37 °C. Double-positive cells were quantified using the Scanford cell analyser (Stanford Shared facility) and analysed by FlowJo 10.1r5, as previously described 17 . Statistical significance was determined by one-way or two-way ANOVA with Bonferroni's correction using Prism 5 (Graphpad). Flow cytometry. To measure the cell surface expression of CD47, cells were exposed to vehicle or 50 ng ml −1 of TNF-α for 24 h. In some experiments, cells were treated with 1 μ M STS during the last 1 h or 4 h of the incubation, before analysis. The cells were collected in TrypLE (Life Sciences) and stained with anti-CD47 antibodies (AbD Serotec MCA2514GA, clone1/1A4, 1:400) or IgG (eBioscience), followed by Alexa Fluor 488 goat anti-mouse (Life Technologies, 1:400), and then FACS-sorted within 1 h (BD FACSCaliber, 530 nm fluorescence [FL1] and > 575 nm [FL3]). Analysis was performed with FloJo 7.6.3. Immunocytochemistry. Primary mouse aortic SMCs were seeded at approximately 60% confluence in glass-bottom culture dishes (MatTek Corporation). Following treatment with TNF-α and/or STS, as described above, cells were rinsed with PBS and fixed with freshly prepared 4% PFA (Fisher Scientific). Once permeabilized with 0.1% Triton X-100 (Sigma), cells were incubated with blocking buffer (3% BSA, Cell Signaling Technology) for 1 h and then incubated overnight at 4 °C with a CD47 antibody (1:80; R&D Systems, Cat# AF1866-SP). After rinsing with PBS, cells were incubated in the dark with a donkey anti-goat Alexa Fluor 594 conjugate secondary antibody (1:1000; Life Technologies) for 1 h then briefly incubated with DAPI. CD47 and DAPI localization was captured at 20× magnification using a Leica DMI3000 B microscope capable of taking fluorescent images. Studies using primary human coronary artery SMCs were also performed as above, but used 5% goat serum blocking buffer (ThermoFisher Scientific), and the following primary and secondary antibodies: CD47 antibody (Novus Biologicals, 1:50); HMGB1 (abcam, ab18256 1:100)); Alexa Fluor 594 goat antimouse (Life Technologies A11005, 1:300); and Alexa Fluor 488 goat anti-rabbit (Life Technologies, A11034). In some studies, exogenous CD47 peptide was preincubated with the cells before the CD47 antibody was applied, as described above. Luciferase reporter assay. CD47 LightSwitch Promoter Reporter GoClones (RenSP, S710450), empty promoter vectors (S790005) and Cypridina TK Control constructs (pTK-Cluc, SN0322S) were obtained from SwitchGear Genomics and transfected into HEK cells using lipofectamine 2000 (Invitrogen). For overexpression assays, expression plasmids for Nfkb1 (p50), Rela (p65), Nfkb2 (p52), and c-Rel were obtained from Addgene (#21965, #21966, #23289, #27256, respectively). Empty vector pCMV4 was generated by HindIII digestion of #21966, and pcDNA3.1 was obtained from Life Technologies. 50 ng of plasmid was co-transfected with 45 ng of the RenSP reporter and 5 ng of the pTK-Cluc reporter construct. Media was changed to fresh DMEM and 50 ng ml −1 of TNF-α was added 2, 8, 24, and 36 h before collection. The cell lysate and supernatant were collected 48 h after transfection and dual luciferase activity was measured with the LightSwitch Dual Assay System using a SpectraMax L luminometer (Molecular Devices), according to the manufacturer's instructions. Relative luciferase activity (Renilla/Cypridina luciferase ratio) was quantified as the percentage change relative to the basal values obtained from control-transfected cells not exposed to TNF-α treatment. Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) was performed according to the Millipore Magna-ChIP protocol with slight modifications. HCASMC were cultured in normal growth media until approximately 75% confluent. Cells were fixed in 1% formaldehyde for 10 min to cross-link chromatin, followed by quenching with glycine for 5 min at room temperature. 2 × 10 7 cells per condition were collected, and nuclear lysates were prepared according to the manufacturer's protocol. Cross-linked chromatin nuclear extracts were sheared into approximately 500 bp fragments using a Bioruptor (Diagenode) for 3 cycles of 3 min (30 s on, 30 s off). Sheared chromatin was clarified via centrifugation at 4 °C for 10 min. 1 × 10 6 nuclei per condition was incubated with 2 μ g rabbit IgG or anti-NF-κ B p105/p50 antibody (Abcam, Ab7971) plus protein A/G magnetic beads overnight at 4 °C on a rotating platform to capture the protein-DNA complexes. Complexes were washed in low salt, high salt, LiCl, and TE buffers and then eluted with a ChIP Elution Buffer containing Proteinase K. Free DNA was subsequently purified using spin columns. Total enrichment was measured using primers designed based on the sequence of the top NfkB binding site within the CD47 promoter: forward (− 804 to − 781): 5′ -ATAGGGAAGAGCAGAGCGAGTAGA-3′ and reverse (+ 627 to + 609): 5′ -GCGTGGACCAGGACACCTA-3′ ), or a negative control region using the following primers: forward: 5′ -CCGGAAGCACTTCTCCTAGA-3′ and reverse: 5′ -AAGAGAGAGCGGAAGTGACG-3′ . Quantitative real-time PCR (ViiA 7, Life Technologies) was performed using SYBR Green (Applied Biosystems) assays and fold enrichment was calculated by measuring the Δ Δ C t -Δ Δ C t IgG. Melting curve analysis was also performed for each ChIP primer. Data are presented as the percentage of input DNA and as fold enrichment of chromatin precipitated with the NF-κ B antibodies relative to the control IgG. In some experiments, cells were treated with TNF-α for 90 min and 24 h before isolation of nuclear lysates. Statistical analysis. Aside from the microarray data (described above), all experimental data are presented as mean ± s.e.m. Data were subjected to the Kolmogorov-Smirnov test to determine distribution. Groups were compared using the Mann-Whitney U test for non-parametric data or the two-tailed Students t-test for parametric data. When comparing multiple groups, data were analysed by analysis of variance with one way ANOVA followed by Tukey's or Dunnett's posthoc test. For multiple testing of parametric data, a value of P < 0.05 was considered statistically significant. In vitro experiments were replicated at least in triplicate and all analyses were performed in a blinded fashion by two separate investigators, unless otherwise specified. In the in vivo intervention studies, comparison was made between mice treated with anti-CD47 antibodies and IgG. In the in vivo synergy studies, ANOVA was performed as above with multiple comparison and linear trend post-testing across all four groups. In the in vitro studies, comparison was made between the intervention (anti-CD47 antibodies) and control (IgG) arms. 'Vehicle control' was only used in experiments where an additional treatment (for example, TNF, oxLDL, infliximab) was studied. In the TaqMan-based CD47 expression experiments, changes were demonstrated as mRNA fold-change compared to the baseline condition (set as '1'). In the microarray-based experiments, relative expression differences were displayed across conditions (for example, atherosclerosis versus no atherosclerosis). In the in vitro phagocytosis assays, efferocytosis rates are displayed as percent of maximum, as previously described 41 . Statistical analysis was performed with GraphPad Prism 5. Aside from the human plaque microarray studies (displayed as Tukey box plots) and the correlation plots (displayed as the 95% confidence band of the best fit line), all error bars display the standard error of the mean. 
Extended Data Figure 3 | Anti-CD47 antibody reduces atherosclerotic burden in several orthogonal in vivo models. a, Study timeline detailing osmotic minipump implantation and high-fat feeding to induce atherosclerosis in the apoE −/− and 'angiotensin infusion' model used herein. Kaplan-Meier curves indicate no change in mortality with anti-CD47 treatment during 28 days of follow up. b, c, Additional representative examples confirm that anti-CD47 antibody reduces atherosclerosis content in the aortic sinus (b) and reduces the percentage of the en face aorta covered by atherosclerotic plaque (c). d-g, Several additional atherosclerosis models were also used in this study to confirm the beneficial effects of anti-CD47 antibody therapy, and to model additional aspects of human cardiovascular disease, including a 'chronic atherosclerosis' model, where antibody therapy was given for 12 weeks (with no angiotensin infusion) (d); a 'plaque vulnerability' model, where the impact of antibody therapy on plaque rupture and intraplaque haemorrhage was quantified (e); an 'established disease' model, where therapy was given for 7 weeks after mice had already developed advanced plaques of equivalent size (f); and a 'reduced dose' model, where the dose of anti-CD47 antibody was reduced by 75%, relative to the preceding studies (g). h, Additionally, a 'short term' study was performed where mice with established lesions of equivalent size and identical apoptosis rates were pulsed for only 5 days with anti-CD47 antibodies before collection, to quantify the effect of therapy on efferocytosis rates, independent of lesion size (phagocytic index indicated by the ratio of 'free' (white stars) to 'associated' (white arrows) apoptotic bodies). Additional methodological details are provided in the Methods. Comparisons made by two-tailed t-tests. * * P < 0.03, * P < 0.05. Error bars represent the s.e.m. Original magnification, × 4 (b, d-f) , × 2 (c), × 10 (h). 10 (a, d) , × 4 (c, e).
Extended Data Figure 6 | Full-dose anti-CD47 antibody therapy induces anaemia, but does not appear to alter NO elaboration, TSP1-dependent signalling, or other processes relevant to vascular biology. a, No significant change in blood pressure is observed between mice treated with IgG or anti-CD47 antibodies, arguing against a systemic difference in nitric oxide (NO) production due to antibody therapy. b, Direct measurement of pulmonary NO release via the Griess reaction indicates that anti-CD47 antibody does not increase NO elaboration in vivo. c, Western blot analysis of cultured murine vascular cells reveals that anti-CD47 antibody has no effect on the expected induction of p38 and ERK phosphorylation secondary to TSP1 treatment. d, Similarly, anti-CD47 antibody has no effect on TSP1-dependent inhibition of eNOS phosphorylation, nor acetylcholine-dependent induction of eNOS phosphorylation. e, MTT assays show that anti-CD47 antibody does not affect cellular proliferation rates in the presence of TSP1. f, In vitro efferocytosis assays show that the expected basal increase in phagocytosis observed after apoptotic cells are exposed to TSP1 (black bars) is not altered in the presence of anti-CD47 antibodies (red bars). (g). Compared to mice receiving control IgG, mice receiving anti-CD47 antibody treatment have similar body weights at baseline and at time of killing. h, No difference is observed for the weight of any organ between groups, with the exception of splenomegaly observed in the anti-CD47-treated animals. i, Histological analysis of the explanted splenic tissue reveals an increase in the red pulp of anti-CD47 treated mice without any change in fibrosis or white pulp content, suggestive of increased erythrophagocytosis in this reticuloendothelial organ. j-l, Dot plots detail the haemoglobin count (j), reticulocyte count (k) and circulating monocyte count (l) for each animal in the acute 4-week angiotensin-infusion atherosclerosis model. Note that this anaemia appears to be self-limited, and no anaemia was observed in the chronic atherosclerosis model or the reduced dose model (P = 0.54 and 0.57, respectively). m, mRNA analysis of aortic tissue reveals that anti-CD47 antibody has no significant effect on the expression of macrophage-polarization factors in vivo. n, Anti-CD47 antibody also has no effect on the aortic expression of any other candidate efferocytosis genes. o-r, Additional quantitative analyses reveals that anti-CD47 antibody has no effect on in vivo neutrophil content (as assessed by Ly6G + area normalized to lesion size) (o); macrophage content (as assessed by Mac-3 + area normalized to lesion size) (p); T-cell content (as assessed by CD3 + area across the lesion and adventitia) (q); or smooth muscle cell content (as quantified by α -SMA + area in the aortic sinus from the external elastic lamina to the lumen) (r). s, t, Anti-CD47 antibody also had no effect on lipid level (s) or serum insulin (t). u, MTT assays reveal that anti-CD47 antibody has no effect on the proliferation of primary aortic SMCs obtained from apoE −/− mice either at baseline (left) or in the presence of 10% serum (right). Comparisons made by two-tailed t-tests, unless otherwise specified. * * * P < 0.001, * * P < 0.01, * P < 0.05. Error bars represent the s.e.m. For gel source data, see Supplementary  Fig. 1; for 
Extended Data Figure 7 | Additional bioinformatic and experimental analyses further implicate a central role for TNF-α in vascular CD47 signalling. a, Cytoscape network visualization of the genes which are significantly correlated with CD47 expression in both human and murine atherosclerotic plaque reveals a high number of TNF-α -related factors (indicated in blue), including ligands, receptors, and downstream signalling factors. b, PANTHER pathway analysis of those genes which were significantly associated with CD47 expression in mouse and human vascular tissue and have been previously associated with atherosclerosis through the STAGE study 43 , identifies 'inflammation mediated by chemokine and cytokine signaling pathway' as the most over-abundant pathway associated with CD47 expression in vascular tissue. c, Using the Hybrid Mouse Diversity Panel (HMDP), which correlates aortic gene expression with Luminex cytokine array data of plasma samples from over 100 inbred strains of mice, we found that vascular CD47 expression is positively correlated with three inflammatory cytokines in vivo, including TNF-α , IL-2 and CXCL1. Correlation data shown for CD47 and TNF-α . d, Co-expression studies confirm that TNF-α and CD47 expression are positively correlated in human carotid endarterectomy samples from the BiKE validation study. The Pearson correlation coefficient was determined assuming a Gaussian distribution and P values were determined using a two-tailed test. e, Experiments with primarily cultured mouse aortic SMCs indicate that TNF-α reproducibly induces Cd47 mRNA upregulation, whereas a number of other classical pro-atherosclerotic stimuli have no significant effect. Notably, CXCL1, IL4, TGF-β and IL-2 fail to induce CD47 expression in vitro, as assessed by ANOVA. f, Additional studies suggest that the effect of TNF-α on CD47 expression persists in the presence of oxLDL, as occurs in the atherosclerotic plaque. g, Western blotting confirms that TNF-α induces CD47 expression in vascular cells at the protein level. For gel source data, see Supplementary Fig. 1 . h, Immunocytochemistry studies of HCASMCs confirm that CD47 expression is induced on the cell surface of TNF-α treated cells. TNF-α effect is assessed by co-staining for HMGB1, and antibody specificity is confirmed with isotype control and recombinant CD47 peptide quenching assays. i, Multiple assays (including FACS, TaqMan and immunocytochemistry studies) reveal that CD47 expression is downregulated on vascular SMCs during programmed cell death, as has previously been observed with inflammatory cells. j, Confirmatory assays in cultured human coronary artery SMCs reveal that TNF-α induces changes similar to those observed in murine cells (Fig. 3d) , including an induction of CD47 under physiological conditions and a blunting of its expected downregulation during apoptosis. Original magnification, × 20. k, The capacity of TNF-α to impair CD47 downregulation during programmed cell death is also observed in mouse SMCs simultaneously exposed to pro-apoptotic stimuli and oxLDL. l, No correlation between CD47 and other candidate cytokines was observed in the BiKE biobank, further supporting a specific relationship between CD47 and TNF-α . m, Representative FACS-based apoptosis panels from cells exposed to the conditions used in Fig. 3g confirm that TNF-α suppresses efferocytosis (Fig. 3g ) despite increasing programmed cell death. Comparisons made by two-tailed t-tests, unless otherwise specified. * * * P < 0.001, * P < 0.05. Error bars represent the s.e.m.
